A carregar...
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. METHODS: Patients received oral dovitinib 500 mg day(−1), 5 d...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5672922/ https://ncbi.nlm.nih.gov/pubmed/28850565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.290 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|